Real-World Effectiveness of Semaglutide for Weight Loss Outcomes in a Community Clinic
Description
Background: The use of Semaglutide, commonly known as Ozempic, has faced public scrutiny in recent years with many viewing it as an expedient strategy for weight loss compared to lifestyle modifications (i.e., diet, exercise). However, research has shown its effectiveness in the treatment of obesity as it slows down gastric emptying, signals the brain to feel satiated, thereby reducing appetite and increasing weight loss. Most studies have investigated the 2.4mg formulation of Semaglutide for weight loss. However, other formulations (e.g., 0.25 and 1.0mg) have not been thoroughly studied within this context, yet may have better implications for patients (e.g., cost, accessibility). Objective: This study aims to investigate the real-world effectiveness of Semaglutide 1.0mg for weight loss in a community clinic primarily focused on obesity care. It is hypothesized that Semaglutide 1.0mg will facilitate clinically meaningful weight loss in patients with obesity at specified intervals of 3-, 6-, 12-, and 24-months. Proposed Methods: This study will employ a retrospective chart review methodology. Participants were included if they were prescribed Semaglutide and adhered to the maximally tolerated dose of up to 1.0mg for at least 12 weeks between January 2021 and March 2023. Clinically relevant variables will be extracted. Changes in BMI and percent change in weight will be analyzed at the specified intervals after initiating Semaglutide. Future applications: These findings may support using Semaglutide 1.0mg as a cost-effective, accessible alternative for obesity management. This study could inform clinical guidelines and policies, address accessibility barriers, and promote equitable obesity care.
Real-World Effectiveness of Semaglutide for Weight Loss Outcomes in a Community Clinic
Background: The use of Semaglutide, commonly known as Ozempic, has faced public scrutiny in recent years with many viewing it as an expedient strategy for weight loss compared to lifestyle modifications (i.e., diet, exercise). However, research has shown its effectiveness in the treatment of obesity as it slows down gastric emptying, signals the brain to feel satiated, thereby reducing appetite and increasing weight loss. Most studies have investigated the 2.4mg formulation of Semaglutide for weight loss. However, other formulations (e.g., 0.25 and 1.0mg) have not been thoroughly studied within this context, yet may have better implications for patients (e.g., cost, accessibility). Objective: This study aims to investigate the real-world effectiveness of Semaglutide 1.0mg for weight loss in a community clinic primarily focused on obesity care. It is hypothesized that Semaglutide 1.0mg will facilitate clinically meaningful weight loss in patients with obesity at specified intervals of 3-, 6-, 12-, and 24-months. Proposed Methods: This study will employ a retrospective chart review methodology. Participants were included if they were prescribed Semaglutide and adhered to the maximally tolerated dose of up to 1.0mg for at least 12 weeks between January 2021 and March 2023. Clinically relevant variables will be extracted. Changes in BMI and percent change in weight will be analyzed at the specified intervals after initiating Semaglutide. Future applications: These findings may support using Semaglutide 1.0mg as a cost-effective, accessible alternative for obesity management. This study could inform clinical guidelines and policies, address accessibility barriers, and promote equitable obesity care.
https://scholar.uwindsor.ca/we-spark-conference/2025/postersessions/7